GleamWall
中文EN

IXHL Incannex Healthcare Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1873875 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY69.0%
TTM EPS YoY97.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-20.7%
ROA-19.9%
ROIC (approx.)-1,944.8%
Asset turnover—

Leverage & solvency

Liabilities / assets6.0%
Debt / equity0.00x
Current ratio67.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.21x
Accruals ratio-15.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30
Income statement
Revenue$0$86,000
R&D expense$5.21M$10.75M
SG&A expense$17.82M$13.13M
Operating income-$23.03M-$23.79M
Interest expense$0$303,000
Pretax income-$19.30M-$46.88M
Income tax$0$0
Net income-$19.30M-$46.88M
EBITDA-$22.79M-$23.54M
EPS (basic)-1.66-40.82
EPS (diluted)-1.66-40.82
Weighted avg. shares (diluted)11.66M1.15M
Balance sheet
Cash & equivalents$67.71M$15.04M
Current assets$72.83M$19.96M
PP&E, net$4,000$227,000
Total assets$72.98M$20.45M
Current liabilities$1.49M$6.98M
Total liabilities$5.61M$7.06M
Shareholders' equity$67.37M$13.39M
Shares outstanding12.54M6.48M
Cash flow statement
Operating cash flow-$12.87M-$12.51M
Capital expenditure$10,000$8,000
Free cash flow-$12.88M-$12.52M
Investing cash flow-$94,000-$8,000
Financing cash flow$65.90M$21.40M
Depreciation & amortization$240,000$246,000
Stock-based compensation$7.56M$2.61M
Share buybacks$9.40M$0

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.